COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Cultural creations made by Chinese women with disabilities showcased at UN headquarters
- China-Europe conference advances vocational education, AI talent
- China completes 75% of summer wheat harvest
- China and South Africa strengthen defense ties at 10th meeting
- China-ASEAN trade grows 9.1%, boosting Guangxi's role
- 5.8-magnitude quake hits waters off Taiwan: CENC
